Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (3541)	11/13/2002 10:36:01 AM
From: wolfdog2	Read Replies (2) \| Respond to of 10345

The question, Fred, is how much Avinza is really worth and how much dilution there is going to be.

To: fred hayes who wrote (3541)	11/13/2002 11:00:18 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 10345

LGND puzzles me: 3 approvals and a good existing deal with Elan for Avinza (the drugs they manufacturing for small markets probably have the same 70% gross margin as Avinza, but they don't have to make it.) The company apparently has a decent pipeline and good partnerships. But, they still haven't reached breakeven and management constantly guides high instead of managing expectations properly. I still believe Avinza will sell very well. Once they get the co-promotion in place, I think this deal will look very good for both companies. Especially so for Elan if they turn around and buy the Lyons back on the market.